Cargando…

Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review

The introduction of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML) has significantly increased survival rate and quality of life for patients with CML. Despite the high efficacy of imatinib, not all patients benefit from this treatment. Resistance to imatinib ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morozova, E.V., Vlasova, Y.Y., Pryanishnikova, M.V., Lepik, K.V., Afanasyev, B.V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674012/ https://www.ncbi.nlm.nih.gov/pubmed/26673003 http://dx.doi.org/10.4137/BMI.S22438

Ejemplares similares

Extramedullary blast crisis of secondary CML accompanying marrow fibrosis
por: Go, Jai Hyang, et al.
Publicado: (2012)

Isolated central nervous system blast crisis in a case of chronic myeloid leukemia on dasatinib
por: Kiran, P. K., et al.
Publicado: (2018)

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report
por: Ostendorf, Benjamin N, et al.
Publicado: (2015)

Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2013)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

New dosing schedules of dasatinib for CML and adverse event management
por: Wong, Siu-Fun
Publicado: (2009)

Co-occurrence of CML Blast Crisis and Severe COVID 19 Infection: A Case Report
por: Khaja, Misbahuddin, et al.
Publicado: (2022)

MR-1 blocks the megakaryocytic differentiation and transition of CML from chronic phase to blast crisis through MEK dephosphorylation
por: Zhao, W, et al.
Publicado: (2013)

ARE/SUZ12 dual specifically-regulated adenoviral TK/GCV system for CML blast crisis cells
por: Zu, Bailing, et al.
Publicado: (2015)

Hoxa9 and Hoxa10 induce CML myeloid blast crisis development through activation of Myb expression
por: Negi, Vijay, et al.
Publicado: (2017)

Correction to: ARE/SUZ12 dual specifically-regulated adenoviral TK/GCV system for CML blast crisis cells
por: Zu, Bailing, et al.
Publicado: (2022)

Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML
por: Niederwieser, Christian, et al.
Publicado: (2021)

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
por: Masiello, David, et al.
Publicado: (2009)

The Combination of Interferon-Alpha and Ponatinib Enables Faster and Deeper Molecular Responses in Patient with De Novo Blast Crisis of CML: Interferon-Alpha May Return as a CML Treatment
por: Hayashi, Kunio, et al.
Publicado: (2021)

PVR and ICAM-1 on Blast Crisis CML Stem and Progenitor Cells with TKI Resistance Confer Susceptibility to NK Cells
por: Kim, Nayoung, et al.
Publicado: (2020)

Blast Crisis of CML After TKI Discontinuation in a Patient With Previous Stable Deep Molecular Response: Is It Safe to Stop?
por: Papalexandri, Apostolia, et al.
Publicado: (2018)

Dasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: A case report
por: LAI, SHIUE-WEI, et al.
Publicado: (2015)

Dasatinib and FLAG-IDA Is an Effective Therapy for Initial Myeloid Blast Crisis but Involves a High Risk of Opportunistic Infections
por: Labrador, Jorge, et al.
Publicado: (2020)

Deep Molecular Response Achieved with Chemotherapy, Dasatinib and Interferon α in Patients with Lymphoid Blast Crisis of Chronic Myeloid Leukaemia
por: Vráblová, Lucia, et al.
Publicado: (2023)

Blast Crisis
por: Kirwin, Margaret, et al.
Publicado: (2020)

Impact of frontline treatment approach on outcomes of myeloid blast phase CML
por: Saxena, Kapil, et al.
Publicado: (2021)

Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation
por: Sigl, M, et al.
Publicado: (2013)

The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group
por: Iriyama, Noriyoshi, et al.
Publicado: (2017)

Cobicistat as a Potential Booster of Ponatinib and Dasatinib Exposure in a CML Patient: A Case Study
por: Hofman, Susan, et al.
Publicado: (2023)

P673: ASCIMINIB MANAGMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH T315I MUTATION.
por: Kuzmina, Elena, et al.
Publicado: (2023)

Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome
por: Tcvetkov, Nikolai, et al.
Publicado: (2020)

Hyperphosphatemia during spontaneous tumor lysis syndrome culminate in severe hypophosphatemia at the time of blast crisis of Ph(neg) CML to acute myelomoncytic leukemia
por: Salomon, Ophira, et al.
Publicado: (2012)

Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model
por: Kazemi-Sefat, Golnaz Ensieh, et al.
Publicado: (2022)

Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis
por: Boucher, Lara, et al.
Publicado: (2023)

High-risk additional chromosomal abnormalities at low blast counts herald death by CML
por: Hehlmann, Rüdiger, et al.
Publicado: (2020)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
por: Hochhaus, Andreas, et al.
Publicado: (2013)

Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
por: Glauche, Ingmar, et al.
Publicado: (2018)

Embryonic Program Activated during Blast Crisis of Chronic Myelogenous Leukemia (CML) Implicates a TCF7L2 and MYC Cooperative Chromatin Binding
por: Desterke, Christophe, et al.
Publicado: (2020)

Author Correction: Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model
por: Kazemi‑Sefat, Golnaz Ensieh, et al.
Publicado: (2023)

Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML
por: Hehlmann, Rüdiger, et al.
Publicado: (2020)

S152: COMBINATORY THERAPY OF ASCIMINIB AND PONATINIB WAS EFFECTIVE IN THE TREATMENT OF BLAST PHASE CML CDX MODEL
por: Čuřík, Nikola, et al.
Publicado: (2023)

Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy
por: Haaß, Wiltrud, et al.
Publicado: (2015)

Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis
por: Godoy, C.R.T., et al.
Publicado: (2015)

Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F
por: Pastore, Friederike, et al.
Publicado: (2013)

A case report and case review: Chronic myeloid leukemia (CML) blast phase with myelomastocytic differentiation
por: Song, Jinming, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m1dsnnaop6ckcddkr58f2k84il